About Pharmacodia
Pharmacodia is a company based in Beijing (China) founded in 2013. Pharmacodia has raised $14.52 million across 3 funding rounds from investors including Yuan Ming Capital, 3E Bioventures Capital and Shanghai Hanshi Investment Management Co. Pharmacodia operates in a competitive market with competitors including MMIT Network, Causaly, ScienceIO, Collaborative Drug Discovery and Posos, among others.
- Headquarter Beijing, China
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.52 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Yuan Ming Capital
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Pharmacodia
Pharmacodia has successfully raised a total of $14.52M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pharmacodia
Pharmacodia has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Yuan Ming Capital, 3E Bioventures Capital and Shanghai Hanshi Investment Management Co.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm focused on medicine based companies
|
Locked | Locked | Locked | |
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Locked | Locked | Locked | |
|
Manufactures and supplies artificial quartz, stone plates, and other building materials.
|
Locked | Locked | Locked |
Investor details for Pharmacodia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharmacodia
Investment portfolio details for Pharmacodia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pharmacodia
Detailed financials for Pharmacodia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmacodia Comparisons
Peer comparison for Pharmacodia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pharmacodia
Pharmacodia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MMIT Network, Causaly, ScienceIO, Collaborative Drug Discovery and Posos, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Offers formulary data & analytics for market research, medication decision & formulary management
|
|
| Locked | Locked | Locked |
AI-based data-mining tools for scientific evidence discovery are provided.
|
|
| Locked | Locked | Locked |
Provider of AI solutions transforming medical text into enriched healthcare data
|
|
| Locked | Locked | Locked |
Biological and chemical data are managed securely in a database.
|
|
| Locked | Locked | Locked |
AI-based drug information and patient profiling tool for healthcare professionals
|
|
| Locked | Locked | Locked |
Application with curated drug information used by physicians
|
Detailed competitors of Pharmacodia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmacodia
Complete news archive for Pharmacodia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmacodia
Pharmacodia was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Pharmacodia is headquartered in Beijing, China.
Pharmacodia is a funded company, having raised a total of $14.52M across 3 funding rounds to date.
Pharmacodia was founded in 2013 in Beijing, China, and operates in the pharmaceutical research and development sector. Big data and information service solutions are provided through its flagship product, Drug Delivery Data V.2.0, an online platform. This platform hosts a database covering drugs, global approvals, clinical trials, patent information, and scientific literature, supporting RD activities worldwide.
Pharmacodia's top competitors include Causaly, MMIT Network and ScienceIO.
Pharmacodia has 3 investors. Key investors include Yuan Ming Capital, 3E Bioventures Capital, and Shanghai Hanshi Investment Management Co.